Technical Analysis for AADI - Aadi Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.42 | -2.74% | -0.04 |
AADI closed down 2.74 percent on Monday, July 1, 2024, on 1.2 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -2.74% | |
| 180 Bearish Setup | Bearish Swing Setup | -2.74% | |
| Expansion Breakdown | Bearish Swing Setup | -2.74% | |
| Reversal New Lows Setup | Bearish Swing Setup | -2.74% |
| Alert | Time |
|---|---|
| Down 2 % | about 5 hours ago |
| Down 1% | about 5 hours ago |
| Reversal New Lows Entry | about 5 hours ago |
| Bearish 180 Entry | about 5 hours ago |
| Fell Below Previous Day's Low | about 5 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/07/2024
Aadi is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. Aadi’s lead product is FYARRO (sirolimus albumin-bound nanoparticles for injectable suspension; nab-sirolimus; ABI-009), an mTOR inhibitor bound to human albumin that has demonstrated significantly higher tumor accumulation, greater mTOR target suppression, and increased tumor growth inhibition over other mTOR inhibitors in preclinical models.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Disease Oncology Tumor Antineoplastic Drugs Drug Delivery Signal Transduction mTOR Mtor Inhibitors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Disease Oncology Tumor Antineoplastic Drugs Drug Delivery Signal Transduction mTOR Mtor Inhibitors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.24 |
| 52 Week Low | 1.42 |
| Average Volume | 227,844 |
| 200-Day Moving Average | 2.81 |
| 50-Day Moving Average | 1.79 |
| 20-Day Moving Average | 1.68 |
| 10-Day Moving Average | 1.61 |
| Average True Range | 0.10 |
| RSI (14) | 30.07 |
| ADX | 23.47 |
| +DI | 12.42 |
| -DI | 31.72 |
| Chandelier Exit (Long, 3 ATRs) | 1.58 |
| Chandelier Exit (Short, 3 ATRs) | 1.73 |
| Upper Bollinger Bands | 1.87 |
| Lower Bollinger Band | 1.48 |
| Percent B (%b) | -0.15 |
| BandWidth | 23.35 |
| MACD Line | -0.08 |
| MACD Signal Line | -0.06 |
| MACD Histogram | -0.0189 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.59 | ||||
| Resistance 3 (R3) | 1.60 | 1.57 | 1.56 | ||
| Resistance 2 (R2) | 1.57 | 1.52 | 1.56 | 1.55 | |
| Resistance 1 (R1) | 1.49 | 1.50 | 1.48 | 1.48 | 1.54 |
| Pivot Point | 1.46 | 1.46 | 1.45 | 1.45 | 1.46 |
| Support 1 (S1) | 1.38 | 1.41 | 1.37 | 1.37 | 1.30 |
| Support 2 (S2) | 1.35 | 1.39 | 1.34 | 1.29 | |
| Support 3 (S3) | 1.27 | 1.35 | 1.28 | ||
| Support 4 (S4) | 1.26 |
